EF Hutton Acquisition Co. I began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR – Get Rating) in a research note released on Monday, Benzinga reports. The brokerage issued a buy rating and a $24.00 price target on the stock.
Other equities research analysts have also issued research reports about the company. Brookline Capital Management reissued a buy rating on shares of Monopar Therapeutics in a research report on Monday, October 3rd. Maxim Group raised their target price on Monopar Therapeutics to $8.00 in a research report on Wednesday, November 16th. Finally, Roth Capital reissued a buy rating on shares of Monopar Therapeutics in a research report on Friday, December 9th.
Monopar Therapeutics Price Performance
MNPR stock opened at $3.22 on Monday. The firm has a market capitalization of $41.60 million, a P/E ratio of -3.98 and a beta of 0.89. The business’s 50-day moving average is $2.57 and its two-hundred day moving average is $2.22. Monopar Therapeutics has a 1 year low of $1.39 and a 1 year high of $4.88.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Monopar Therapeutics stock. UBS Group AG increased its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Rating) by 529.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,561 shares of the company’s stock after buying an additional 16,455 shares during the quarter. UBS Group AG owned about 0.16% of Monopar Therapeutics worth $45,000 as of its most recent SEC filing. 1.55% of the stock is owned by institutional investors.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
- Get a free copy of the StockNews.com research report on Monopar Therapeutics (MNPR)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.